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ABSTRACT 
 
Title : A PROSPECTIVE RANDOMISED OPEN LABEL 
COMPARATIVE STUDY OF EFFICACY AND SAFETY OF 
ESCITALOPRAM VERSUS SERTRALINE IN MAJOR DEPRESSIVE 
DISORDER IN A TERTIARY CARE HOSPITAL. 
Background:  
  Depression is a commonly occuring mental health disorder affecting all 
sectors of people worldwide. Mental health is equally emphasised as that of 
physical health. Depression, an exasperating disorder shows alarming hike in 
the present and recent past.  Selective serotonin reuptake inhibitors  are first 
choice of drugs for depression and  frequently prescribed. Still it has not been 
possible to declare one particular drug to be more efficacious than the other. 
The purpose of this study is to compare two of the drugs from this class of 
SSRIs, namely Sertraline and Escitalopram, in terms of efficacy and safety 
among major depressive disorder patients. 
Aim: 
 To compare the efficacy and safety of two anti depressants, 
Escitalopram and Sertraline in patients diagnosed with major depressive 
disorder in outpatient department of psychiatry in a tertiary care hospital in 
Chengalpattu. 
Methodology: 
After approval from Institutional Ethical Committee, 120 patients were 
recruited and randomised into either group A to receive Tab.Escitalopram  
10-20mg/day or group B to receive Tab.Sertraline 50-200mg/day. 
Demographic details and complete history were recorded during enrolment. 
Clinical examination, screening with Hamilton depression rating scale and lab 
investigations were done at baseline. Efficacy was measured by  response in 
terms of improvement of symptoms assessed by scoring with Hamilton 
Depression Rating Scale at baseline, at 4, 8, and 12 weeks. Safety was 
ensured by recording vitals of the patients and laboratory parameters  at 
baseline, 4, 8, 12 weeks of study period. Safety was assessed by recording 
adverse drug reactions reported voluntarily or observed clinically or changes 
reported in lab investigation during follow up.  
Results: 
Mean HAM-D score reduction from 20.77 to 8.75 in group A 
(Escitalopram) and  20.96 at baseline to 8.65 in group B (Sertraline) after  
12 weeks therapy was statistically significant within groups. Response rate 
assessed by reduction of mean HAM-D score did not show statistically 
significant difference between two groups. The occurrence of adverse effects 
in sertraline group was higher than escitalopram group and this difference was 
found to be statistically significant (P=0.007). 
Conclusion: 
The study confirms that both Escitalopram and Sertraline are 
appropriate as first line  drugs in  treatment for depression. Both drugs 
showed equal efficacy in producing response and remission. Escitalopram 
was better tolerated with less number of reported adverse events than 
sertraline.  
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